Literature DB >> 10980839

Recent trials of antithrombotics in the management of patients with acute coronary syndromes.

R A Harrington1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10980839     DOI： 10.1007/s11886-999-0020-1

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


× No keyword cloud information.
  11 in total

1.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.

Authors:  M Cohen; C Demers; E P Gurfinkel; A G Turpie; G J Fromell; S Goodman; A Langer; R M Califf; K A Fox; J Premmereur; F Bigonzi
Journal:  N Engl J Med       Date:  1997-08-14       Impact factor: 91.245

2.  Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.

Authors:  D F Kong; R M Califf; D P Miller; D J Moliterno; H D White; R A Harrington; J E Tcheng; A M Lincoff; V Hasselblad; E J Topol
Journal:  Circulation       Date:  1998 Dec 22-29       Impact factor: 29.690

Review 3.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

4.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators.

Authors:  E M Antman; R P Giugliano; C M Gibson; C H McCabe; P Coussement; N S Kleiman; A Vahanian; A A Adgey; I Menown; H J Rupprecht; R Van der Wieken; J Ducas; J Scherer; K Anderson; F Van de Werf; E Braunwald
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

5.  Mortality by cause for eight regions of the world: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-03       Impact factor: 79.321

6.  Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.

Authors:  A Oler; M A Whooley; J Oler; D Grady
Journal:  JAMA       Date:  1996-09-11       Impact factor: 56.272

7.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

Review 8.  TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators.

Authors:  E M Antman
Journal:  Am Heart J       Date:  1998-06       Impact factor: 4.749

9.  Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1998-12       Impact factor: 24.094

10.  Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators.

Authors:  L K Newby; W R Rutsch; R M Califf; M L Simoons; P E Aylward; P W Armstrong; L H Woodlief; K L Lee; E J Topol; F Van de Werf
Journal:  J Am Coll Cardiol       Date:  1996-06       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.